GlassScriptPhysician profile
Sanjeev Saxena
NPI 1093701120
$5,346.36
in general payments reported to CMS, 2019-2025
20 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2021: $485 · 2022: $476 · 2023: $941 · 2024: $2,570 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,172 · Food and Beverage: $1,503 · Consulting Fee: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,172.18 |
| Food and Beverage | $1,502.81 |
| Consulting Fee | $380.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,326.75 | 2019-2025 | Ekosonic, Ranger, Jetstream Sc |
| Novartis Pharmaceuticals Corporation | $970.29 | 2019-2023 | Leqvio |
| Merit Medical Systems INC | $424.67 | 2025 | |
| Becton, Dickinson and Company | $380.00 | 2024 | |
| Medtronic, INC. | $308.98 | 2021 | |
| Paratek Pharmaceuticals, INC. | $151.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $147.40 | 2021-2022 | |
| Melinta Therapeutics, LLC | $125.00 | 2023 | Kimyrsa |
| Philips North America LLC | $124.28 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $100.30 | 2025 | |
| Galderma Laboratories, L.P. | $88.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.98 | 2019-2022 | |
| Tactile Systems Technology INC | $47.36 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Janssen Scientific Affairs, LLC | $22.30 | 2021 | |
| Bard Peripheral Vascular, INC. | $20.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $19.44 | 2024 | |
| Vifor Pharma, INC. | $12.86 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.